Literature DB >> 24996550

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2).

Akira Marui1, Takeshi Kimura2, Noboru Nishiwaki3, Kazuaki Mitsudo4, Tatsuhiko Komiya5, Michiya Hanyu6, Hiroki Shiomi2, Shiro Tanaka7, Ryuzo Sakata8.   

Abstract

Ischemic heart disease is a major risk factor for morbidity and mortality in patients with end-stage renal disease. However, long-term benefits of percutaneous coronary intervention (PCI) relative to coronary artery bypass grafting (CABG) in those patients is still unclear in the drug-eluting stent era. We identified 388 patients with multivessel and/or left main disease with end-stage renal disease requiring dialysis among 15,939 patients undergoing first coronary revascularization enrolled in the Coronary REvascularization Demonstrating Outcome Study in Kyoto PCI/CABG Registry Cohort-2 (PCI: 258 patients and CABG: 130 patients). The CABG group included more patients with 3-vessel (38% vs 57%, p <0.001) and left main disease (10% vs 34%, p <0.001). Preprocedural Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score in the CABG group was significantly higher than that in the PCI group (23.5 ± 8.7 vs 29.4 ± 11.0, p <0.001). Unadjusted 30-day mortality was 2.7% for PCI and 5.4% for CABG. Cumulative 5-year all-cause mortality was 52.3% for PCI and 49.9% for CABG. Propensity score-adjusted all-cause mortality was not different between PCI and CABG (hazard ratio [HR] 1.33, 95% confidence interval [CI] 0.85 to 2.09, p = 0.219). However, the excess risk of PCI relative to CABG for cardiac death was significant (HR 2.10, 95% CI 1.11 to 3.96, p = 0.02). The risk of sudden death was also higher after PCI (HR 4.83, 95% CI 1.01 to 23.08, p = 0.049). The risk of myocardial infarction after PCI tended to be higher than after CABG (HR 3.30, 95% CI 0.72 to 15.09, p = 0.12). The risk of any coronary revascularization after PCI was markedly higher after CABG (HR 3.78, 95% CI 1.91 to 7.50, p <0.001). Among the 201 patients who died during the follow-up, 94 patients (47%) died from noncardiac morbidities such as stroke, respiratory failure, and renal failure. In patients with multivessel and/or left main disease undergoing dialysis, 5-year outcomes revealed that CABG relative to PCI reduced the risk of cardiac death, sudden death, myocardial infarction, and any revascularization. However, the risk of all-cause death was not different between PCI and CABG.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24996550     DOI: 10.1016/j.amjcard.2014.05.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Cardiovascular complications in chronic dialysis patients.

Authors:  Thomas A Mavrakanas; David M Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-11       Impact factor: 2.894

2.  Influence of chronic kidney disease on the outcome of patients with chronic total occlusion.

Authors:  Qing-Bin Zhang; Li-Ming Chen; Min Li; Yu-Qi Cui; Chuan-Yan Zhao; Lian-Qun Cui
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

3.  Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.

Authors:  Sripal Bangalore; Yu Guo; Zaza Samadashvili; Saul Blecker; Jinfeng Xu; Edward L Hannan
Journal:  J Am Coll Cardiol       Date:  2015-09-15       Impact factor: 24.094

4.  Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD.

Authors:  Marc Saad; Boutros Karam; Geovani Faddoul; Youssef El Douaihy; Harout Yacoub; Hassan Baydoun; Christine Boumitri; Iskandar Barakat; Chadi Saifan; Elie El-Charabaty; Suzanne El Sayegh
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-01-22

Review 5.  Impact of coronary artery bypass surgery and percutaneous coronary intervention on mortality in patients with chronic kidney disease and on dialysis: A systematic review and meta-analysis.

Authors:  Pravesh Kumar Bundhun; Akash Bhurtu; Meng-Hua Chen
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

6.  Evaluation of a protocol for coronary artery disease investigation in asymptomatic elderly hemodialysis patients.

Authors:  Jose Jayme G De Lima; Luis Henrique W Gowdak; Flavio J de Paula; Henrique Cotchi S Muela; Elias David-Neto; Luiz A Bortolotto
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-14

7.  Long-Term Outcomes in Coronary Artery Bypass Graft Patients Using Internal Thoracic Artery with Ipsilateral Arteriovenous Shunt for Hemodialysis.

Authors:  Yung-Szu Wu; Shih-Rong Hsieh; Hao-Ji Wei; Chiann-Yi Hsu; Chung-Lin Tsai
Journal:  Acta Cardiol Sin       Date:  2019-07       Impact factor: 2.672

8.  Optimal treatment strategies for coronary artery disease in patients with advanced kidney disease: a meta-analysis.

Authors:  Jingwen Yong; Jinfan Tian; Xin Zhao; Xueyao Yang; Haoran Xing; Yi He; Xiantao Song
Journal:  Ther Adv Chronic Dis       Date:  2021-07-07       Impact factor: 5.091

9.  Revascularisation of patients with end-stage renal disease on chronic haemodialysis: bypass surgery versus PCI-analysis of routine statutory health insurance data.

Authors:  Martin Möckel; Julia Searle; Henning Thomas Baberg; Peter Dirschedl; Benny Levenson; Jürgen Malzahn; Thomas Mansky; Christian Günster; Elke Jeschke
Journal:  Open Heart       Date:  2016-10-03

10.  Extracorporeal shock wave treatment attenuated left ventricular dysfunction and remodeling in mini-pig with cardiorenal syndrome.

Authors:  Jiunn-Jye Sheu; Hani E E Ali; Ben-Chung Cheng; Hsin-Ju Chiang; Pei-Hsun Sung; Kuan-Hung Chen; Chih-Chao Yang; Yen-Ta Chen; John Y Chiang; Pao-Yuan Lin; Sarah Chua; Han-Tan Chai; Sheng-Ying Chung; Cheuk-Kwan Sun; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.